Recent researches reported that CD4 + T lymphocytes and CD8 + T lymphocytes infiltrating in tumor could improve the efficacy of tumor-targeted vaccine or adoptive immune cell therapy, which had been proved effective in patients with melanoma, head and neck cancer, breast cancer, and lung cancer [44–46]. This evidence concerns the gene CD8A and lung carcinoma.